Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.

Ophthalmology - 1 Jan 2014

Miyake Masahiro, Yamashiro Kenji, Akagi-Kurashige Yumiko, Kumagai Kyoko, Nakata Isao, Nakanishi Hideo, Oishi Akio, Tsujikawa Akitaka, Yamada Ryo, Matsuda Fumihiko, Yoshimura Nagahisa

Abstract excerpt

PURPOSE: To investigate the association between the vascular endothelial growth factor (VEGF) gene polymorphism and the response to anti-VEGF treatment for choroidal neovascularization (CNV) in highly myopic eyes. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 357 unrelated highly myopic Japanese patients with axial lengths ≥26.0 mm in both eyes were eligible, and 83 patients who received anti-VEGF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Aptamers, Nucleotide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Choroidal Neovascularization

Share to Fluorescein Angiography

Share to Myopia, Degenerative

Share to Ophthalmoscopy

Share to Tomography, Optical Coherence

Source

Identifiers

PMID: 23953100
DOI: 10.1016/j.ophtha.2013.06.043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.PMID 23953100Read ↗

Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes.Semantic proximity Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

Genetic factors for choroidal neovascularization associated with high myopia.Semantic proximity Read ↗

Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes.Semantic proximity Read ↗

Evaluation of 10 AMD Associated Polymorphisms as a Cause of Choroidal Neovascularization in Highly Myopic Eyes.Semantic proximity Read ↗

Genetic and environmental factors related to the development of myopic maculopathy in Spanish patients.Semantic proximity Read ↗

Vascular endothelial growth factor gene polymorphisms and risk of neovascular age-related macular degeneration in a Chinese cohort.Semantic proximity Read ↗

Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration.Semantic proximity Read ↗

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.Semantic proximity Read ↗

Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia.Semantic proximity Read ↗

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.Semantic proximity Read ↗

An Updated and Comprehensive Meta-Analysis of Association between VEGA -634G > C, -460T > C, +405G > C and +936C > T Polymorphisms and Retinopathy of Prematurity Risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.